Evidence map›Paper›PMID 41000563›Full record

ArticleO&G open2025

Hereditary Leiomyomatosis and Renal Cell Cancer in a Patient With Isolated Uterine Leiomyomas.

Shakiba Ardestani, Meghan McGrattan, Brittany Gillies, Raymond H Kim, Mara Sobel

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shakiba ArdestaniDepartment of Obstetrics and Gynecology, University of Toronto, the University Health Network, the Department of Genetics, Princess Margaret Cancer Centre, the Department of Genetics and the Department of Obstetrics and Gynecology, Mount Sinai Hospital, the Department of Genetics, Hospital for Sick Children, and the University of Toronto, Toronto, Ontario, Canada.
Meghan McGrattanDepartment of Obstetrics and Gynecology, University of Toronto, the University Health Network, the Department of Genetics, Princess Margaret Cancer Centre, the Department of Genetics and the Department of Obstetrics and Gynecology, Mount Sinai Hospital, the Department of Genetics, Hospital for Sick Children, and the University of Toronto, Toronto, Ontario, Canada.
Brittany GilliesDepartment of Obstetrics and Gynecology, University of Toronto, the University Health Network, the Department of Genetics, Princess Margaret Cancer Centre, the Department of Genetics and the Department of Obstetrics and Gynecology, Mount Sinai Hospital, the Department of Genetics, Hospital for Sick Children, and the University of Toronto, Toronto, Ontario, Canada.
Raymond H KimDepartment of Obstetrics and Gynecology, University of Toronto, the University Health Network, the Department of Genetics, Princess Margaret Cancer Centre, the Department of Genetics and the Department of Obstetrics and Gynecology, Mount Sinai Hospital, the Department of Genetics, Hospital for Sick Children, and the University of Toronto, Toronto, Ontario, Canada.
Mara SobelDepartment of Obstetrics and Gynecology, University of Toronto, the University Health Network, the Department of Genetics, Princess Margaret Cancer Centre, the Department of Genetics and the Department of Obstetrics and Gynecology, Mount Sinai Hospital, the Department of Genetics, Hospital for Sick Children, and the University of Toronto, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare autosomal dominant syndrome that is characterized by renal cell carcinoma, cutaneous leiomyomas, and uterine leiomyomas. Although HLRCC is usually identified in individuals with multiple cutaneous leiomyomas or a personal or family history of renal cell carcinoma, advances in histopathology have allowed detection of HLRCC in myomectomy and hysterectomy specimens. CASE: A 36-year-old patient with a large leiomyoma was referred to gynecology for heavy menstrual bleeding. After no response to medical management, she proceeded with elective myomectomy. Fumarate hydratase (FH) immunohistochemical staining of the myomectomy specimen and subsequent molecular genetic analysis of the

conclusionAs more patients with HLRCC are identified with a primary presentation of leiomyomas, it is essential that gynecologists are familiar with this diagnosis. Health care professionals should inquire about skin lesions and family history of renal cell carcinoma in patients with symptomatic leiomyomas and refer patients with risk factors or pathology findings suggestive of HLRCC for genetic counseling.

Identifiers

PMID41000563
PMCPMC12456520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.